Merit Medical Systems (MMSI) Bank of America Global Healthcare Conference 2026 summary

Leadership transition and organizational changes

• Transitioned from founder-led to founder-inspired, focusing on scaling beyond $1.5 billion in revenue.

• Established eight cross-functional platform teams to drive ownership and growth across product lines.

• Added resources in reimbursement and global enterprise excellence to strengthen internal capabilities.

• Undergoing a robust strategic planning process, with current CGI goals set through 2026.

• Tracking well toward CGI goals, with updates on future strategy expected late this year or early next.

Segment reporting and business structure

• Shifted external reporting to align with internal management, now segmented as Foundational and Therapeutic.

• Foundational products include enabling devices like syringes and catheters, with a 6% CAGR over three years.

• Therapeutic segment includes higher-priced, procedure-centric products such as lead extraction and oncology devices.

• Eight platforms: two foundational, four therapeutic, and two mixed; investments and growth assessed by platform.

• Foundational products have gross margins just below corporate average, while therapeutic products are above.

Growth drivers and innovation strategy

• Growth in foundational driven by broad utilization across procedures like EP, TAVR, and biopsies.

• Therapeutic growth led by new launches (e.g., C2 CryoBalloon, Resilience stent, OneMark) and high-growth areas like embolics.

• WRAPSODY, the first in-house PMA product, reset for competitive pricing and targeted $7M U.S. revenue.

• Innovation strategy balances proactive platform reviews with opportunistic M&A, focusing on customer needs and make-vs-buy decisions.

• No plans to expand beyond current eight platforms; focus remains on strategic, adjacent product additions.